WO2023072085A1 - 异丙基-d-吡喃葡萄糖苷衍生物、制备方法及其用途 - Google Patents

异丙基-d-吡喃葡萄糖苷衍生物、制备方法及其用途 Download PDF

Info

Publication number
WO2023072085A1
WO2023072085A1 PCT/CN2022/127414 CN2022127414W WO2023072085A1 WO 2023072085 A1 WO2023072085 A1 WO 2023072085A1 CN 2022127414 W CN2022127414 W CN 2022127414W WO 2023072085 A1 WO2023072085 A1 WO 2023072085A1
Authority
WO
WIPO (PCT)
Prior art keywords
tritium
deuterium
hydrogen
chemical formula
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/127414
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
陈令仪
王翊
廖彣玲
李育棠
吕亭萱
黄郁文
李家维
王贞
陈方仪
焦传金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202280071353.3A priority Critical patent/CN118139869A/zh
Priority to KR1020247017445A priority patent/KR20240090982A/ko
Priority to US18/704,860 priority patent/US20250255893A1/en
Priority to JP2024547816A priority patent/JP2024541121A/ja
Priority to EP22885962.5A priority patent/EP4424694A4/en
Publication of WO2023072085A1 publication Critical patent/WO2023072085A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Definitions

  • the invention provides an isopropyl-D-glucopyranoside (Isopropyl-D-glucopyranoside) derivative and a synthesis method thereof, and the use of the Isopropyl-D-glucopyranoside derivative for promoting nerve repair.
  • Isopropyl-D-glucopyranoside isopropyl-D-glucopyranoside derivative and a synthesis method thereof, and the use of the Isopropyl-D-glucopyranoside derivative for promoting nerve repair.
  • Traumatic Brain Injury affect about 70 million people worldwide each year.
  • Common treatments include physical therapy, hyperbaric oxygen therapy, cranial magnetic stimulation, and cranial direct current stimulation. These non-invasive treatments can improve depression and cognitive function after TBI, but there are still no effective drugs that can promote nerve regeneration after brain injury.
  • Traumatic brain injury is an injury caused by external force hitting the brain. There are nearly 70 million confirmed cases worldwide every year. Traumatic brain injury can damage the cranial nerves, leading to loss of movement or cognitive function of the patient. Because the central nervous system is difficult to regenerate and restore after being damaged, there is currently no effective therapy for nerve regeneration in traumatic brain injury. Patients with traumatic brain injury often have brain lesions after a period of time and will cause brain degenerative diseases in the future. Therefore, the early use of drugs that promote brain nerve regeneration after brain injury is a therapeutic solution.
  • the human nervous system is divided into central nervous system and peripheral nervous system, both of which are composed of neurons.
  • the trigeminal nerve is the cranial nerve in the peripheral nerves and connects to the pons (central nerve). Therefore, when the compound of the present invention penetrates the nasal mucosa, passes through the olfactory epithelial cells, enters the channels around the sense of smell and the trigeminal nerve, and enters the brain, it can also achieve the effect of systemic nerve repair through the peripheral nerves.
  • cranial nerves that are not easy to repair are used as experimental objects. In this way, both the central and peripheral nerves in the nervous system can be repaired.
  • the "central nervous system” consists of the brain and spinal cord.
  • the "central nervous system” described in the present invention includes but is not limited to the olfactory brain, amygdala, hippocampus, neocortex, lateral ventricle, superior optic thalamus, optic thalamus, hypothalamus, bottom optic thalamus, pituitary gland, pineal gland body, third ventricle, midbrain tectum, peduncle, anterior part of the brain, cerebral aqueduct, pons, cerebellar medulla, spinal cord.
  • the "peripheral nervous system” consists of the somatic nervous system and the autonomic nervous system.
  • the "peripheral nerves” mentioned in the present invention include but not limited to sensory nerves, motor nerves, cranial nerves, spinal nerves, sympathetic nerves, parasympathetic nerves, and enteric nervous system.
  • the present invention provides a kind of isopropyl-D-glucopyranoside (Isopropyl-D-glucopyranoside) derivative, has the chemical structure shown in chemical formula (1):
  • R1 is the chemical structure shown in chemical formula (2) or chemical formula (3) that can be substituted or unsubstituted;
  • R2 and R3 are chemical structures shown in chemical formula (4) or chemical formula (5) which may be substituted or not;
  • R4 is hydrogen, deuterium, tritium, hydroxyl, or halogen
  • R5 is hydrogen, deuterium, tritium, hydroxyl, carbonyl, or halogen
  • R6 is hydrogen, deuterium, tritium, hydroxyl, carbonyl, or halogen
  • R7 is hydrogen, deuterium, tritium, hydroxyl, or halogen
  • R1" is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R2 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R3 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • R4" is methyl, ethyl, propyl, hydrogen, deuterium, or tritium.
  • the Isopropyl-D-glucopyranoside derivatives of the present invention comprise compounds of the formula:
  • the R1 is methyl, ethyl, propyl, hydrogen, deuterium, tritium or hydroxyl;
  • the R2 is methyl, ethyl, propyl, hydrogen, deuterium, tritium or hydroxyl;
  • the R3 is methyl, ethyl, propyl, hydrogen, deuterium or tritium;
  • the R4 is methyl, ethyl, propyl, hydrogen, deuterium or tritium;
  • the R5 is hydrogen, deuterium, tritium, hydroxyl, carbonyl or halogen
  • Said R6 is hydrogen, deuterium, tritium, hydroxyl or halogen.
  • the present invention uses "Isopropyl-D-glucopyranoside derivatives” for "treatment of nerve damage".
  • the present invention uses "snake grape ionone glycoside (Ampelopsisionoside)” and “blumenol” in “Isopropyl-D-glucopyranoside derivatives”.
  • the compound of the following chemical formula (6) in the Isopropyl-D-glucopyranoside derivatives of the present invention is prepared by the following chemical synthesis steps:
  • R1 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or is hydroxyl
  • R2 is methyl, ethyl, propyl, Hydrogen, deuterium, tritium, or hydroxyl
  • R3 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium
  • R4 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • said dialkylation reaction is carried out by electrophilic reagent 1, and said electrophilic reagent 1 is methyl iodide, ethyl iodide, propyl iodide, MeOTf, EtOTf, PrOTf, propyl bromide/sodium iodide or dimethyl sulfate; the acylating reagent is formaldehyde, acetaldehyde or propionaldehyde; this intermediate is further subjected to an alkyne nucleophilic addition reaction to obtain compound (8).
  • the alkyne nucleophilic addition reagent comprises an alkyne having an R4 functional group, and a base comprising n-butyllithium (nBuLi), lithium diisopropylamide (LDA), bis(trimethylsilyl Base) lithium amide (LHMDS, wherein the functional group of R4 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • nBuLi n-butyllithium
  • LDA lithium diisopropylamide
  • LHMDS bis(trimethylsilyl Base) lithium amide
  • the compound shown in chemical formula (8) first utilizes electrophilic reagent 2 and amine reagent to react under low temperature conditions in the olefination reaction, and then produces the compound shown in chemical formula (9);
  • electrophilic reagent 2 is formazan mesyl chloride, tosyl chloride, acetic anhydride, benzoic anhydride, methyl iodide or dimethyl sulfate;
  • the amine reagents are triethylamine, di Ethylamine, pyridine, pyrrolidine, ethyldisiopropylamine, 2,6-lutidine or 1,4-diazabicyclo[ 2.2.2] octane (1,4-diazabicyclo[2,2,2]octane);
  • the temperature of the low temperature condition is -30 to 25°C; after completion, the second base is then added to complete the olefination, so
  • the second base is potassium tert-butyrate (P
  • the compound shown in chemical formula (9) utilizes sugar chain reagent 1 to react through described sugar chain reaction, obtains the compound shown in chemical formula (10), wherein said sugar chain reagent 1 is nickel sulfide/trifluoromethanesulfonic acid Silver (NIS/AgOTf), sodium tetrabromophenolphthalein sulfonate/tri-tert-butylphenol/trifluoromethanesulfonic anhydride (BSP/TTBP/Tf2O), trimethylsilyl trifluoromethanesulfonate/nickel sulfide (TMSOTf/NIS ), trimethylsilyl trifluoromethanesulfonate (TMSOTf), silver trifluoromethanesulfonate (AgOTf) or CuOTf, wherein the reaction temperature of the sugar chain reaction is -78 to 0°C;
  • reagent 1 is acetic acid aqueous solution, hydrochloric acid aqueous solution, trifluoroacetic acid Aqueous solution, TsOH and H 2 O, HCl dissolved in 1,4-dioxane mixed solution (HCL in 1,4-dioxane) or sulfuric acid aqueous solution; followed by the debenzoyl reaction, the debenzoyl reaction Utilize debenzoyl reagent to carry out, wherein said debenzoyl reagent is sodium hydroxide, sodium methoxide, sodium ethoxide, potassium hydroxide, potassium methoxide, potassium ethoxide, hydrochloric acid methanol solution, hydrochloric acid aqueous solution, trifluoroacetic acid (TFA) with H 2 O or sulfuric acid
  • R1 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R2 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R3 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • R4 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium.
  • the compound represented by the following chemical formula (12) in the Isopropyl-D-glucopyranoside derivatives of the present invention is prepared by the following chemical synthesis steps:
  • said conversion comprises deprotection of acetal, isomerization, stereoselective deoxidation and deprotection of benzoyl, wherein said deprotection of acetal and said isomerization are carried out with an acidic reagent
  • the acidic reagent is a mixed solution of acetic acid aqueous solution, hydrochloric acid aqueous solution, trifluoroacetic acid (TFA) and H 2 O, TsOH and H 2 O, HCl dissolved in 1,4-dioxane (1,4-dioxane) (HCL in 1,4-dioxane) or aqueous sulfuric acid; followed by stereoselective deoxidation at first low temperature conditions with reducing agent 2 NaBH 4 , LiAlH 4 , sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , Et 3 SiH/BF 3 -Et 2 O, lithium tri-sec-butylborohydride (
  • R1 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R2 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R3 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • R4 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium.
  • the compound represented by the following chemical formula (13) in the Isopropyl-D-glucopyranoside derivatives of the present invention is prepared by the following chemical synthesis steps:
  • said transformation comprises regioselective and stereoselective 1,4-reduction/carbonyl reduction; said regioselective and stereoselective 1,4-reduction is carried out with reducing agent 3 under a second low temperature condition, said Reductant 3 is NaBH 4 , LiAlH 4 , sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 ) ] 6 ,, DIBAL or H 2 , Pd/C; the equivalent of the reducing agent 3 is 0.5, 1.0, 2.0, 3.0, 4.0 or 5.0 equivalents; the regioselectivity and the stereoselectivity of 1,4-reduction
  • the temperature of the second low temperature condition described in the step is -78 to 25°C;
  • R1 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R2 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R3 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • R4 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium.
  • the compound described in the following chemical formula (14) among the Isopropyl-D-glucopyranoside derivatives of the present invention is prepared by the following chemical synthesis steps:
  • the reducing agent 4 is sodium borohydride, lithium aluminum hydride, sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 Butyl lithium borohydride (L-selectride), [CuH(PPh 3 )] 6 , diisobutyl aluminum hydride (DIBAL), H 2 /Pd/C or RhCl(PPH 3 ) 3 /H 2 ; the reaction temperature of the selective alkene reduction reaction is -78 to 25°C;
  • R1 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R2 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R3 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • R4 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium.
  • the compound represented by the following chemical formula (15) among the Isopropyl-D-glucopyranoside derivatives of the present invention is prepared by the following chemical synthesis steps:
  • the deketalization and the isomerization reaction utilize deketalization and isomerization
  • the reaction reagents are carried out, and the deketalization and isomerization reaction reagents are acetic acid aqueous solution, hydrochloric acid aqueous solution, trifluoroacetic acid aqueous solution, TsOH and H 2 O, HCl is dissolved in the mixed solution of 1,4-dioxane (HCL in 1, 4-dioxane) or sulfuric acid aqueous solution
  • the subsequent described debenzoyl protection reaction utilizes debenzoyl protection reagent to carry out, and described debenzoyl protection reagent is sodium hydroxide, sodium methylate, sodium ethylate, potassium hydroxide , potassium methylate, potassium ethylate, methanolic hydrochloric acid solution, aqueous hydrochloric acid
  • R1 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R2 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R3 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • R4 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium.
  • the compound shown in the following chemical formula (16) and the compound shown in chemical formula (17) in the Isopropyl-D-glucopyranoside derivatives of the present invention are prepared by the following chemical synthesis steps:
  • the compound shown in the chemical formula (15) is converted into a compound shown in the chemical formula (16) and a compound shown in the chemical formula (17) through a selective reduction reaction;
  • the compound shown in chemical formula (15) carries out described selective reduction reaction and obtains the compound shown in chemical formula (16) and the compound shown in chemical formula (17) by selective reduction reaction reagent
  • described selective reduction reaction reagent is sodium borohydride, Lithium aluminum hydride, sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , lithium tri-sec-butyl borohydride (L-selectride), [CuH(PPh 3 )] 6 , diisobutyl hydride Aluminum (diisobutyl aluminum hydride (DIBAL)) or H 2 /Pd/C; the reaction temperature of the selective reduction reaction is -78 to 25°C;
  • R1 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R2 is methyl, ethyl, propyl, hydrogen, deuterium, tritium, or hydroxyl;
  • R3 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium;
  • R4 is methyl, ethyl, propyl, hydrogen, deuterium, or tritium.
  • the Isopropyl-D-glucopyranoside derivatives of the invention have relatively low toxicity to Neuro2a cells.
  • the present invention further provides an application of Isopropyl-D-glucopyranoside derivatives for promoting nerve repair.
  • Isopropyl-D-glucopyranoside derivatives can promote regeneration of injured hippocampal neurons (injured hippocampal neurons) and promote nerve regeneration in 3D brain tissue slices when used alone, proving that the compound can effectively promote neuronal regeneration and can be used to repair nerve damage.
  • the Isopropyl-D-glucopyranoside derivatives of the present invention can promote the repair of retinal nerves.
  • the Isopropyl-D-glucopyranoside derivatives of the present invention can cross the user's blood-brain barrier and enter the brain through nasal administration, so as to promote the repair of the damaged neurons.
  • the Isopropyl-D-glucopyranoside derivatives of the present invention can penetrate the blood-brain barrier and enter the brain, so as to promote the repair and regeneration of brain nerves or increase the number of nerves.
  • the Isopropyl-D-glucopyranoside derivatives of the present invention can promote the regeneration of cortical neurons after traumatic brain injury.
  • the effective dosage concentration of the Isopropyl-D-glucopyranoside derivative used in the present invention is 9.674 nM to 1342 ⁇ M.
  • the Isopropyl-D-glucopyranoside derivatives of the present invention have significant effects on nerve repair, wherein nasal administration compounds can penetrate the blood-brain barrier (blood-brain barrier) and enter the brain to promote the repair of damaged neurons ; promote the repair, regeneration or increase of the number of nerves in the brain; and promote the regeneration of nerve axes of cortical neurons and hippocampal neurons after traumatic brain injury.
  • blood-brain barrier blood-brain barrier
  • 1A-1C are the results of cytotoxicity experiments of Isopropyl-D-glucopyranoside derivatives of the present invention.
  • Fig. 2 is a flow chart of the present invention in vitro (in vitro) nerve repair test.
  • Fig. 3 is a schematic diagram of calculating the gap closure rate (gap closure rate) of the present invention to quantify relative nerve axis regeneration.
  • 4A-4B are the results of nerve repair experiments on hippocampal nerve cells in vitro (in vitro) of the Isopropyl-D-glucopyranoside derivative Ampelopsisionoside of the present invention.
  • Fig. 5 is the result of the nerve repair experiment of the Isopropyl-D-glucopyranoside derivative Ampelopsisionoside in vitro (in vitro) of cortical nerve cells of the present invention.
  • Fig. 6 is the result of nerve repair experiment of hippocampal nerve cells in vitro (in vitro) by Isopropyl-D-glucopyranoside derivative Byzantionoside B of the present invention.
  • Fig. 7 shows the results of the nerve repair experiment of the Isopropyl-D-glucopyranoside derivative Byzantionoside B in vitro (in vitro) of cortical nerve cells of the present invention.
  • Fig. 8 is the result of the nerve repair experiment of the Isopropyl-D-glucopyranoside derivative Roseoside in vitro (in vitro) of the hippocampal nerve cells of the present invention.
  • Fig. 9 is the result of the nerve repair experiment of the Isopropyl-D-glucopyranoside derivative Roseoside in vitro (in vitro) of cortical nerve cells of the present invention.
  • Fig. 10 is a flow chart of the experiment of ex vivo brain tissue slices of the present invention.
  • Figure 11 shows the experimental results of three-dimensional brain tissue slices of the Isopropyl-D-glucopyranoside derivative Ampelopsisionoside of the present invention (ex vivo).
  • Fig. 12 is the experimental results of three-dimensional brain tissue slices of Isopropyl-D-glucopyranoside derivative Byzantionoside B of the present invention (ex vivo).
  • Fig. 13 is the experimental results of three-dimensional brain tissue slices of the Isopropyl-D-glucopyranoside derivative Roseoside in vitro (ex vivo) of the present invention.
  • Fig. 14 is the experimental flow chart of the present invention to control cortical impact brain trauma model and the experimental results of Isopropyl-D-glucopyranoside derivative Ampelopsisionoside promoting the recovery of exercise ability of rats after brain trauma.
  • Fig. 15 is the experimental flow chart of the present invention to control cortical impact traumatic brain injury model and the experimental results of the recovery (stress test) of ampelopsisionoside, a derivative of Isopropyl-D-glucopyranoside, promoting the environmental exploration ability of rats after brain trauma.
  • Fig. 16 is a flow chart of the experiment of the Isopropyl-D-glucopyranoside derivative Ampelopsisionoside of the present invention controlling the model of cortical impact traumatic brain injury.
  • Fig. 17 shows the horizontal bar test results of the Isopropyl-D-glucopyranoside derivative Ampelopsisionoside of the present invention controlling cortical impact traumatic brain injury model experiment.
  • Fig. 18 is a flow chart of promoting the repair of retinal nerves in vitro (ex vivo) by Isopropyl-D-glucopyranoside derivative Byzantionoside B of the present invention.
  • Figure 19 shows the experimental results of the Isopropyl-D-glucopyranoside derivative Byzantionoside B of the present invention promoting the repair of retinal nerves in vitro.
  • Fig. 20 is a flowchart of the promotion of retinal nerve repair in ex vivo by Roseoside, an Isopropyl-D-glucopyranoside derivative of the present invention.
  • Figure 21 is the experimental results of the Isopropyl-D-glucopyranoside derivative Roseoside of the present invention promoting the repair of retinal nerves in ex vivo.
  • Fig. 22 is a synthesis flow diagram of various derivatives of Isopropyl-D-glucopyranoside of the present invention.
  • the stem contains snake grape ionone glycoside (Ampelopsisionoside), blumenol C glucoside (Byzantionoside B) and roseoside (Roseoside) for Neuro2a Cell toxicity.
  • the CellTiter-Glo cell viability assay measures the amount of ATP in cells, which in turn quantifies the viability of cells after addition of compounds.
  • Embodiment two Isopropyl-D-glucopyranoside derivative Ampelopsisionoside (in vitro) hippocampal gyrus nerve cell nerve repair test
  • the experimental procedure is shown in Figure 2.
  • the fetal rats of 18-day-pregnant rats were taken out, and then the brains of the fetal rats were divided into cortex and hippocampus, and then the cortex and hippocampus were separated into cortical nerve cells. (cortical neurons) and hippocampal neurons (hippocampal neurons), the hippocampal neurons are planted in a 48-well dish, this day is called Day In Vitro 0 (DIV0), and Cytosine beta (Cytosine beta) will be added at DIV2 -D-arabinoside, AraC) inhibits the proliferation of glial cells.
  • DIV0 Day In Vitro 0
  • Cytosine beta Cytosine beta
  • the nerve cells will be scratched with a micropipette tip, and Ampelopsisionoside (concentration of 9.674nM to 967.4 ⁇ M), 0.1% dimethyl Disulfoxide (DMSO) is the solvent for Ampelopsisionoside.
  • Ampelopsisionoside concentration of 9.674nM to 967.4 ⁇ M
  • DMSO dimethyl Disulfoxide
  • the degree of nerve axis regeneration was quantified by the gap closure rate.
  • the white dotted line is the boundary created by scratching the nerve cells drawn by the tip of the micropipette, and the black part in the middle is the boundary produced by scratching the nerve cells.
  • the calculation method is to draw a line between the gaps every 50 ⁇ m in the injured area to calculate the width of the gap.
  • Embodiment three Isopropyl-D-glucopyranoside derivative Ampelopsisionoside promotes injured cortical nerve cell nerve regeneration experiment in vitro
  • the gap closure rate (gap closure rate) relative to 0.1% DMSO was calculated to quantify the degree of nerve axis regeneration, and the area between the two dotted lines in the immunofluorescence graph represents the injured area.
  • the experimental results show that Ampelopsisionoside can effectively promote the proliferation of cortical neurite.
  • Embodiment four Isopropyl-D-glucopyranoside derivative Byzantionoside B in vitro (in vitro) hippocampal nerve cell nerve repair test
  • the gap closure rate (gap closure rate) relative to ddH 2 O was calculated to quantify the degree of nerve axis regeneration, and the area between the two dotted lines in the immunofluorescence graph represents the injured area.
  • the dotted line in the figure below represents the ddH 2 O group.
  • Embodiment five Isopropyl-D-glucopyranoside derivative Byzantionoside B in vitro (in vitro) cortical nerve cell nerve repair test
  • Embodiment six Isopropyl-D-glucopyranoside derivative Roseoside (in vitro) hippocampal gyrus nerve cell nerve repair test
  • the gap closure rate (gap closure rate) relative to ddH 2 O was calculated to quantify the degree of nerve axis regeneration, and the area between the two dotted lines in the immunofluorescence graph represents the injured area.
  • the dotted line in the figure below represents the ddH 2 O group.
  • Embodiment seven Isopropyl-D-glucopyranoside derivative Roseoside (in vitro) cortical nerve cell nerve repair test
  • Embodiment eight Isopropyl-D-glucopyranoside derivative Ampelopsisionoside ex vivo (ex vivo) three-dimensional brain tissue slice experiment
  • the experimental procedure is shown in Figure 10.
  • the brains of fetal rats were taken out, and the brains were embedded in low-melting point agarose gel.
  • the brains were cut into slices with a thickness of 350 ⁇ m using a Leica microtome VT100. Brain slices were scratched with a knife and cultured, and added ddH 2 O or Ampelopsisside every day. After culturing for 96 hours, neurons were labeled with TUJ1 antibody, glial cells were labeled with GFAP antibody, and nuclei were labeled with DAPI reagent by fluorescent immunostaining. The scale bar of this experiment is 100 ⁇ m. This experiment was shot with a Zeiss LSM800 confocal microscope.
  • the white dotted line is the gap cut by the scalpel, and the right side of the dotted line is the newborn nerve axis.
  • Embodiment nine Isopropyl-D-glucopyranoside derivative Byzantionoside B isolated (ex vivo) brain tissue slice experiment
  • the experimental procedure is shown in Figure 10.
  • the brains of fetal rats were taken out, and the brains were embedded in low-melting point agarose gel.
  • the brains were cut into slices with a thickness of 350 ⁇ m using a Leica microtome VT100. After scratching the brain slices with a knife, they were cultured, and ddH 2 O or Byzantionoside B was added every day. After 96 hours of culture, neurons were labeled with TUJ1 antibody, glial cells were labeled with GFAP antibody, and nuclei were labeled with DAPI reagent by fluorescent immunostaining. Scale bar is 100 ⁇ m. This experiment was shot with a Zeiss LSM800 confocal microscope.
  • Embodiment ten Isopropyl-D-glucopyranoside derivative Roseoside ex vivo (ex vivo) brain tissue slice experiment
  • the experimental procedure is shown in Figure 10.
  • the brains of fetal rats were taken out, and the brains were embedded in low-melting point agarose gel.
  • the brains were cut into slices with a thickness of 350 ⁇ m using a Leica microtome VT100. Brain slices were scratched and cultured, and ddH 2 O or Roseoside was added every day. After 96 hours of culture, neurons were labeled with TUJ1 antibody, glial cells were labeled with GFAP antibody, and nuclei were labeled with DAPI reagent by fluorescent immunostaining.
  • the scale bar of this experiment is 100 ⁇ m. This experiment was shot with a Zeiss LSM800 confocal microscope.
  • Embodiment 11 Isopropyl-D-glucopyranoside derivative Ampelopsisionoside promotes the recovery test of the motor ability of the mice after brain trauma
  • the open-field experiment was used to measure the exercise capacity of mice without brain injury, brain injury, and brain injury given 14 ⁇ g/kg Ampelopsisionoside every day, one or five days later (1day post injury, 1dpi; 5day post injury, 5dpi)
  • the comparison of this experiment uses the control cortical impact traumatic brain injury model (controlled cortical impact model) to carry out brain injury to mice at 0dpi, and at 0, 2, 4, 6, 8, 10, 12dpi ( day post injury) administered 14 ⁇ g/kg of Ampelopsisionoside by nasal administration.
  • Part A is the implementation of this test.
  • the mice are placed in a large white acrylic box that is evenly divided into four grids, and the mice are allowed to move freely for five minutes. Within five minutes, the mice's movements were recorded by a Microsoft LifeCam Cinema camera and analyzed by Anubis track software.
  • Embodiment 12 Isopropyl-D-glucopyranoside derivative Ampelopsisionoside promotes the recovery of the mouse's exploration ability after brain trauma
  • Part A is the implementation of this test.
  • the mice were placed in a large white acrylic box that was evenly divided into four grids, and the mice were allowed to move freely for five minutes. Within five minutes, the mice's movements were recorded by a Microsoft LifeCam Cinema camera and analyzed by Anubis track software.
  • Embodiment 13 Isopropyl-D-glucopyranoside derivative Ampelopsisionoside promotes the recovery of motor coordination after brain injury in mice
  • mice Using the horizontal bar experiment, the mouse was placed on a brass rod with a height of 49 cm from the ground, a length of 38 cm, and a diameter of 2 mm, 4 mm, and 6 mm, and the mouse was allowed to grasp the brass rod with its front paws.
  • the ability of the mice to motor coordination was assessed by the time spent on the rod and whether they reached the platform at the end of the brass rod.
  • the evaluation criteria are as follows: 1 point for 1-5 seconds, 2 points for 5-10 seconds, 3 points for 10-20 seconds, 4 points for 20-30 seconds, and 5 points for more than 30 seconds or reaching the platform.
  • Embodiment 14 Isopropyl-D-glucopyranoside derivative Byzantionoside B promotes ex vivo (ex vivo) retinal nerve repair
  • Retinal explants were obtained from 8-day-old C57BL/6 strain mice, and the eyes were removed after sacrifice, and then the eyeball was separated from the retina with tweezers and micro-scissors and removed. Remove the vitreous body, and finally cut the separated retina into four pieces, trim and scratch the edge of the tissue with micro scissors, culture each piece on a 18mm round glass slide, put it into a 12-well plate, and put it in the incubator , cultured at 5% CO 2 and 35°C for five days, each piece of retinal tissue was replaced with fresh culture medium every day and 13.5 ⁇ M or 135 ⁇ M Byzantionoside B was added.
  • Embodiment 15 Isopropyl-D-glucopyranoside derivative Roseoside promotes ex vivo (ex vivo) retinal nerve repair
  • Retinal explants were obtained from 8-day-old C57BL/6 mice, and the eyes were removed after sacrifice. Then, the eyeball was separated from the retina with tweezers and micro-scissors. Remove the vitreous body, and finally cut the separated retina into four pieces, trim and scratch the edge of the tissue with micro scissors, culture each piece on a 18mm round glass slide, put it into a 12-well plate, and put it in the incubator , cultured at 5% CO2 and 35°C for five days, and each piece of retinal tissue needed to be replaced with fresh culture medium every day and 13 ⁇ M or 130 ⁇ M Roseoside was added.
  • Embodiment 16 Isopropyl-D-glucopyranoside derivative continuous synthesis steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/CN2022/127414 2021-10-25 2022-10-25 异丙基-d-吡喃葡萄糖苷衍生物、制备方法及其用途 Ceased WO2023072085A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202280071353.3A CN118139869A (zh) 2021-10-25 2022-10-25 异丙基-d-吡喃葡萄糖苷衍生物、制备方法及其用途
KR1020247017445A KR20240090982A (ko) 2021-10-25 2022-10-25 이소프로필-d-글루코피라노사이드 유도체, 이의 제조방법과 용도
US18/704,860 US20250255893A1 (en) 2021-10-25 2022-10-25 Isopropyl-d-glucopyranoside derivative, and preparation method therefor and use thereof
JP2024547816A JP2024541121A (ja) 2021-10-25 2022-10-25 イソプロピル-d-グルコピラノシド誘導体、製造方法及びその用途
EP22885962.5A EP4424694A4 (en) 2021-10-25 2022-10-25 ISOPROPYL-D-GLUCOPYRANOSIDE DERIVATIVE, ITS PREPARATION PROCESS AND ITS USE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163271411P 2021-10-25 2021-10-25
US63/271,411 2021-10-25

Publications (1)

Publication Number Publication Date
WO2023072085A1 true WO2023072085A1 (zh) 2023-05-04

Family

ID=86159046

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2022/127414 Ceased WO2023072085A1 (zh) 2021-10-25 2022-10-25 异丙基-d-吡喃葡萄糖苷衍生物、制备方法及其用途
PCT/CN2022/127372 Ceased WO2023072069A1 (zh) 2021-10-25 2022-10-25 异野漆树苷及其衍生物用于促进神经修复的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/127372 Ceased WO2023072069A1 (zh) 2021-10-25 2022-10-25 异野漆树苷及其衍生物用于促进神经修复的用途

Country Status (7)

Country Link
US (2) US20240415859A1 (cg-RX-API-DMAC7.html)
EP (2) EP4424695A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024539499A (cg-RX-API-DMAC7.html)
KR (2) KR20240090982A (cg-RX-API-DMAC7.html)
CN (2) CN118215669A (cg-RX-API-DMAC7.html)
TW (1) TWI898161B (cg-RX-API-DMAC7.html)
WO (2) WO2023072085A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106167508A (zh) * 2016-07-13 2016-11-30 上海应用技术学院 一种具有紫罗兰香味的葡萄糖苷化合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101045072A (zh) * 2007-05-08 2007-10-03 胡军 山香圆叶提取物及其医药用途
CN102617659A (zh) * 2012-03-09 2012-08-01 中国烟草总公司郑州烟草研究院 α-紫罗兰醇葡糖苷的合成方法及其在卷烟中的加香应用
CN102617658B (zh) * 2012-03-09 2014-08-20 中国烟草总公司郑州烟草研究院 β-紫罗兰醇-β-D-葡糖苷的制备方法及其在烟草加香中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106167508A (zh) * 2016-07-13 2016-11-30 上海应用技术学院 一种具有紫罗兰香味的葡萄糖苷化合物及其制备方法

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY 1 November 1995 (1995-11-01), ANONYMOUS : " β-D-Glucopyranoside, 3-(4-hydroxy-2,2,6-trimethylcyclohexyl)-1-methyl- 2-propenyl (9CI) (CA INDEX NAME)", XP093060430, retrieved from STN Database accession no. 169512-17-8 *
DATABASE Registry 12 June 1996 (1996-06-12), ANONYMOUS : "β-D-Glucopyranoside, 3- (1,4-dihydroxy-2,6,6- trimethyl-2-cyclohe xen-1- yl)-1-methylpropyl, [1S-[1α,1(S*),4β]]- (9 CI) (CA INDEX NAM E)", XP093061664, retrieved from STN Database accession no. 177261-75-5 *
DATABASE REGISTRY 16 November 1985 (1985-11-16), ANONYMOUS : "β-D-Glucopyranoside, 1- methyl-3-(2,6,6-trim ethyl-2-cyclohexen1-yl)-2- propen-1-yl (CA IND EX NAME)", XP093060443, retrieved from STN Database accession no. 99049-90-8 *
DATABASE Registry 18 July 2001 (2001-07-18), ANONYMOUS : "β-D-Glucopyranoside, (1 R)-3-[(1S,4S,6R)-4-hy droxy-2,2,6- trimethylcyclohexyl] -1-methylpropyl (CA INDEX NAME)", XP093061651, retrieved from STN Database accession no. 346616-70-4 *
DATABASE Registry 23 February 2011 (2011-02-23), ANONYMOUS : "β-D-Glucopyranoside, 3- [(1S)-1-hydroxy-2,6,6 -trimethyl-2-cyclohe xen-1- yl]-1-methylpropyl (CA INDEX NAME)", XP093061658, retrieved from STN Database accession no. 1263786-31-7 *
DATABASE Registry 24 July 2001 (2001-07-24), ANONYMOUS : "β-D-Glucopyranoside, (1 R)-1-methyl-3-(2,6,6- trimethyl-2-cyclohe xen-1- yl)propyl (CA INDEX NAME)", XP093061661, retrieved from STN Database accession no. 347852-06-6 *
DATABASE Registry 24 July 2001 (2001-07-24), ANONYMOUS : "β-D-Glucopyranoside, (1 S)-1-methyl-3-(2,6,6- trimethyl-2-cyclohe xen-1- yl)propyl (CA INDEX NAME)", XP093061660, retrieved from STN Database accession no. 347852-11-3 *
DATABASE REGISTRY 24 July 2007 (2007-07-24), ANONYMOUS : "β-D-Glucopyranoside, (1 R,2E)-3-[(1R,4S,6R)-4- hydroxy-2,2,6- trimethylcyclohexyl] -1-methyl-2-propen1-yl (CA INDEX NAM E)", XP093060423, retrieved from STN Database accession no. 943234-63-7 *
DATABASE REGISTRY 26 January 1996 (1996-01-26), ANONYMOUS : "β-D-Glucopyranoside, 3- (4-hydroxy-2,6,6-tri methyl-2-cyclohexe n-1-yl)- 1-methyl-2-propen1-yl (CA INDEX NAM E) ", XP093060440, retrieved from STN Database accession no. 172705-15-6 *
DATABASE Registry 27 June 1996 (1996-06-27), ANONYMOUS : "β-D-Galactopyranoside, 1-methyl-3-(2,2,6-tri methylcyclohexyl)pr opyl (CA INDEX NAME)", XP093061647, retrieved from STN Database accession no. 177799-49-4 *
DATABASE Registry 27 June 1996 (1996-06-27), ANONYMOUS : "β-D-Glucopyranoside, 1- methyl-3-(2,2,6-trim ethylcyclohexyl)pro pyl (CA INDEX NAME)", XP093061643, retrieved from STN Database accession no. 177799-46-1 *
DATABASE REGISTRY 28 May 1999 (1999-05-28), ANONYMOUS : "β-D-Glucopyranoside, (2 E)-3-[(4R,6S)-1,4-dihy droxy-2,2,6- trimethylcyclohexyl] -1-methyl-2-propen1-yl (CA INDEX NAME)", XP093060426, retrieved from STN Database accession no. 223586-72-9 *
DATABASE Registry 30 April 2007 (2007-04-30), ANONYMOUS : "β-D-Glucopyranoside, (1 S)-1-(hydroxymethy l)-3-[(1S,4S,6R)-4-hyd roxy2,2,6-trimethylcyclo hexyl]propyl (CA IN DEX NAME)", XP093061654, retrieved from STN Database accession no. 933776-87-5 *
DATABASE REGISTRY 31 August 2012 (2012-08-31), ANONYMOUS : "β-D-Glucopyranoside, (2 E)-1-methyl-3-(2,6,6- trimethyl-2-cyclohe xen-1- yl)-2-propen-1-yl (CA INDEX NAME)", XP093060435, retrieved from STN Database accession no. 1393353-90-6 *
DATABASE REGISTRY 31 August 2012 (2012-08-31), ANONYMOUS : "β-D-Glucopyranoside, (2 E)-1-methyl-3-(2,6,6- trimethyl-2-cyclohe xen-1- yl)-2-propen-1-yl (CA INDEX NAME)", XP093060437, retrieved from STN Database accession no. 1300745-23-6 *
DATABASE REGISTRY 6 April 1994 (1994-04-06), ANONYMOUS : "β-D-Glucopyranoside, 3- (1,4-dihydroxy-2,2,6- trimethylcyclohexyl) -1- methyl-2-propen-1-y l (CA INDEX NAME)", XP093060434, retrieved from STN Database accession no. 154149-05-0 *
DATABASE Registry 7 November 1997 (1997-11-07), ANONYMOUS : "D-Glucopyranoside, 3-cy clohexylpropyl (CA I NDEX NAME) ", XP093061650, retrieved from STN Database accession no. 197016-50-5 *
DATABASE Registry 8 December 2005 (2005-12-08), ANONYMOUS : "β-D-Glucopyranoside, 3- cyclohexylpropyl (C A INDEX NAME)", XP093061640, retrieved from STN Database accession no. 869541-00-4 *
DATABASE REGISTRY 8 January 1994 (1994-01-08), ANONYMOUS : "β-D-Glucopyranoside, 3- (1,4-dihydroxy-2,2,6- trimethylcyclohexyl) -1- methylpropyl, [1R-[1 α,1(R*),4α,6α]]- (9CI) (CA INDEX NAME) ", XP093060445, retrieved from STN Database accession no. 155596-09-1 *
DATABASE REGISTRY 8 July 1994 (1994-07-08), ANONYMOUS : "β-D-Glucopyranoside, (1 R,2E)-3-[(1S,4S,6R)-1, 4-dihydroxy-2,2,6- trimethylcyclohexyl] -1-methyl-2-propen1-yl (CA INDEX NAM E) ", XP093060432, retrieved from STN Database accession no. 156199-49-4 *
DE MARINO SIMONA, BORBONE NICOLA, ZOLLO FRANCO, IANARO ANGELA, DI MEGLIO PAOLA, IORIZZI MARIA: "Megastigmane and Phenolic Components from Laurus nobilis L. Leaves and Their Inhibitory Effects on Nitric Oxide Production", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 52, no. 25, 1 December 2004 (2004-12-01), US , pages 7525 - 7531, XP055907409, ISSN: 0021-8561, DOI: 10.1021/jf048782t *
GODA YUKIHIRO ET AL.: "Constituents in Watercress: Inhibitors of Histamine Release from RBL-2H3 Cells Induced by Antigen Stimulation", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 22, no. 12, 31 December 1999 (1999-12-31), XP055951204, DOI: 10.1248/bpb.22.1319 *
MORIKAWA TOSHIO, YI ZHANG, SEIKOU NAKAMURA, HISASHI MATSUDA, OSAMU MURAOKA, MASAYUKI YOSHIKAWA: "Bioactive Constituents from Chinese Natural Medicines. XXII.1) Absolute Structures of New Megastigmane Glycosides, Sedumosides E1, E2, E3, F1, F2, and G, from Sedum sarmentosum (Crassulaceae)", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 55, no. 3, 1 March 2007 (2007-03-01), pages 435 - 441, XP093060458 *
See also references of EP4424694A4 *

Also Published As

Publication number Publication date
JP2024541121A (ja) 2024-11-06
US20240415859A1 (en) 2024-12-19
TW202320806A (zh) 2023-06-01
CN118215669A (zh) 2024-06-18
KR20240090983A (ko) 2024-06-21
KR20240090982A (ko) 2024-06-21
EP4424694A1 (en) 2024-09-04
TWI898161B (zh) 2025-09-21
WO2023072069A1 (zh) 2023-05-04
US20250255893A1 (en) 2025-08-14
CN118139869A (zh) 2024-06-04
TW202317142A (zh) 2023-05-01
EP4424695A4 (en) 2025-10-22
EP4424695A1 (en) 2024-09-04
JP2024539499A (ja) 2024-10-28
EP4424694A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
Mastenbroek et al. The role of microglia in early neurodevelopment and the effects of maternal immune activation
Dey et al. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease
KR102275631B1 (ko) 직접 세포전환을 기반으로한 신경줄기세포의 성상교세포로의 분화방법
JP2026026410A (ja) 神経筋接合部の保護及び/又は再生剤
JP7500875B2 (ja) 運動ニューロン疾患及び神経筋接合部障害の処置のためのn-(3-(4-(3-(ジイソブチルアミノ)プロピル)ピペラジン-1-イル)プロピル)-1h-ベンゾ[d]イミダゾール-2-アミン硫酸塩及びそれらの溶媒和物の使用
TW202317142A (zh) 異丙基-d-吡喃葡萄糖苷衍生物及其製備方法和用於促進神經修復的用途
US9523081B2 (en) Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases
CN108314737B (zh) 一种重组蛋白及其制备方法和应用
JP2024541121A5 (cg-RX-API-DMAC7.html)
Maclaren Expression of myelin proteins in the opossum optic nerve: Late appearance of inhibitors implicates an earlier non‐myelin factor in preventing ganglion cell regeneration
KR20240138266A (ko) 저강도 집속초음파를 처리하여 내인성 신경줄기세포를 활성화하는 방법
CN107880109A (zh) 一种促红细胞生成素来源肽及其制备方法和用途
CN115212193A (zh) 指甲醌的新用途
CN119139457B (zh) 抗菌肽mu1的应用
RU2814327C1 (ru) ПРИМЕНЕНИЕ СУЛЬФАТНЫХ СОЛЕЙ N-(3-(4-(3-(ДИИЗОБУТИЛАМИНО)ПРОПИЛ)ПИПЕРАЗИН-1-ИЛ)ПРОПИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛ-2-АМИНА И ИХ СОЛЬВАТОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДВИГАТЕЛЬНЫХ НЕЙРОНОВ И НАРУШЕНИЙ НЕРВНО-МЫШЕЧНЫХ СОЕДИНЕНИЙ
TWI823110B (zh) 天南星科萃取物用於促進神經修復的用途
CN120053443B (zh) 金雀花碱-n-亚甲基-(5,7,4’-三羟基)异黄酮在制备治疗脑梗药物的应用
JP2024539499A5 (cg-RX-API-DMAC7.html)
CA3191189C (en) Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
Wang et al. Mesenchymal stem cell therapy in autoimmune eye diseases: Focus on dry eye diseases and autoimmune uveitis
RU2799454C2 (ru) Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение
KR20250079591A (ko) 인간 섬유아세포 유래 신경줄기세포를 이용한 신경계 질환의 예방 또는 치료용 조성물
CN121668317A (zh) Chrna3激动剂在治疗低压低氧应激诱导的记忆下调中的应用
US20200352950A1 (en) Novel method of treating dystonia
HK40089134A (en) Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22885962

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2024547816

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202280071353.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 18704860

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20247017445

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022885962

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202402829R

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2022885962

Country of ref document: EP

Effective date: 20240527

WWP Wipo information: published in national office

Ref document number: 18704860

Country of ref document: US